{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:24:11Z","timestamp":1785929051298,"version":"3.56.0"},"reference-count":23,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Despite the prospective randomized controlled JAVELIN Bladder 100 trial, no real-world evidence exists regarding tumor characteristics, adverse events (AEs), and survival of avelumab maintenance (AVM)-treated patients with partial\/complete response or stable disease after previous platinum-based chemotherapy for advanced\/metastatic urothelial carcinoma (mUC). &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; We relied on our institutional database to identify mUC patients who received AVM between January, 2021 and December, 2023. The main outcomes consisted of overall survival (OS) and progression-free survival (PFS) and were computed by Kaplan-Meier estimates. Stratification was performed according to programmed death ligand 1 (PD-L1) status. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Overall, 24 AVM patients were identified at a median age of 71 (interquartile range [IQR]: 67\u201376) years, of which 67% were males. Of these, 63%, 21%, and 17% received AVM therapy for bladder cancer and upper tract urothelial carcinoma or both, respectively. PD-L1 status was positive in 45% of patients. During AVM treatment, AEs were observed in 33% of patients; however, they were limited to \u22642 grade AEs. At a median follow-up of eight (IQR 4\u201320) months, 71% of patients had progressed under AVM with median PFS of 6.2 months (confidence interval [CI]: 3.2\u201318.2). Median OS was 13.4 (CI: 6.9 \u2013 not reached [NR]) months. One-year OS after AVM was 52%. In PD-L1-positive patients, median PFS and OS were 6.4 (CI: 2.7 \u2013 NR) months and 13.4 (CI: 7.7 months \u2013 NR), respectively. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; AVM is associated with moderate AE rates. Despite similarities in baseline characteristics compared to trial-selected JAVELIN Bladder 100 mUC patients, AVM resulted in longer\/similar PFS but significantly shorter OS in real-world setting. <\/jats:p>","DOI":"10.1159\/000538237","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T22:00:26Z","timestamp":1709935226000},"page":"285-291","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma"],"prefix":"10.1159","volume":"108","author":[{"given":"S\u00e9verine","family":"Banek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Chi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hoeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florestan","family":"Koll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cano Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"K\u00f6llermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kosiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.07.005"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.11.005"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-208973"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000534858"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.12.029"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00540-5"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103534"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0041"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102187"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1188\/23.CJON.71-80"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.06.009"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1159\/000513361"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.07.001"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(23)X0011-8"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0923-7534(23)X0011-8"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/uin\/article-pdf\/108\/4\/285\/4261488\/000538237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/uin\/article-pdf\/108\/4\/285\/4261488\/000538237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:10:58Z","timestamp":1745421058000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000538237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,6]]},"published-print":{"date-parts":[[2024,8,6]]}},"URL":"https:\/\/doi.org\/10.1159\/000538237","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}